RxDoctor Payments Data

Suzann Leslie, DO

Family Medicine · Stuart, FLNPI 1578540829

Payments from drug & device makers

$5,389in general payments, 2019–2025

Across 229 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • EMD Serono, Inc.$403
  • Lilly USA, LLC$325
  • Biogen$227
  • AstraZeneca$218
  • SK Life Science, Inc.$214
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,32699%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,389 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$87,156
Medicare patients
319
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$91,869
OzempicSemaglutide57$68,958
MounjaroTirzepatide30$38,642
XareltoRivaroxaban37$33,198
JanuviaSitagliptin Phosphate31$31,317
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,955
VascepaIcosapent Ethyl30$24,875
JardianceEmpagliflozin15$22,636
ProliaDenosumab12$21,161
JanumetSitagliptin Phos/Metformin Hcl13$18,467
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,960
Breo ElliptaFluticasone/Vilanterol12$6,247
Rosuvastatin Calcium527$6,024
SynthroidLevothyroxine Sodium48$5,038
Albuterol Sulfate HfaAlbuterol Sulfate88$4,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$91,86966 claims
Novo NordiskOzempic$112$68,95857 claims
MerckJanuvia, Janumet$28$49,78444 claims
Lilly USA, LLCMounjaro$325$38,64230 claims
Johnson & JohnsonXarelto$45$33,19837 claims
GSKTrelegy Ellipta, Breo Ellipta$187$31,20233 claims
Boehringer IngelheimJardiance$81$22,63615 claims
AmgenProlia$192$21,16112 claims
AbbVieSynthroid$1,141$5,03848 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$4,025486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →